Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-25 Substudy A in relapsed/refractory Waldenstrom macroglobulinemia
NL-OMON59628Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Apr 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in Waldenström macroglobulinemia (WM), sponsored by Kite Pharma. Started Apr 2023; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NL-OMON59628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59628.